GSK3915393 / GSK - LARVOL DELTA

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - P2 | N=158 | Terminated | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Terminated; The study met futility criteria at pre-planned interim analysis, showing no clinical efficacy of the investigational drug. Based on the lack of efficacy at the interim data review, the sponsor decided to terminate the study.

Trial termination • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - P2 | N=158 | Active, not recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Feb 2026 ➔ Oct 2025 | Trial primary completion date: Feb 2026 ➔ Oct 2025

Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - P2 | N=158 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting

Enrollment closed • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib (clinicaltrials.gov) - P1 | N=50 | Completed | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Completed | N=38 ➔ 50

Enrollment change • Trial completion • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib (clinicaltrials.gov) - P1 | N=38 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P2 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole (clinicaltrials.gov) - P1; N=65; Completed; Sponsor: GlaxoSmithKline; Recruiting ➔ Completed

Trial completion • Celiac Disease • Immunology

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3915393 in Participants With Celiac Disease (CeD) (clinicaltrials.gov) - P1; N=78; Recruiting; Sponsor: GlaxoSmithKline; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Celiac Disease • Immunology • IL2 • PCR

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3915393 in Participants With Celiac Disease (CeD) (clinicaltrials.gov) - P1; N=78; Not yet recruiting; Sponsor: GlaxoSmithKline

Clinical • New P1 trial • Celiac Disease • Immunology